An open-label 2:1 randomized phase I/II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first line treatment of patients with non-resectable metastatic colorectal cancer and k-ras wild type (VOLFI)

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of k-ras wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI (http://www.clinicaltrials.gov)